Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Sign in
Join now
Dipesh Navsaria MPH, MSLIS, MD
Dipesh Navsaria MPH, MSLIS, MD Advisory Board
Robert Bonakdar MD, FAAFP, FACN
Robert Bonakdar MD, FAAFP, FACN Advisory Board
David Rakel MD, FAAFP
David Rakel MD, FAAFP Editor-in-Chief
See All Experts
story of the week
Published in Primary Care and
1 other channel

Journal Scan / Research · August 10, 2021

Improved Safety of ARBs vs ACE Inhibitors as First-Line Treatment

Hypertension

 

 Save  Recommend
 Share

Additional Info

Disclosure statements are available on the authors' profiles:

Ashish Aggarwal MD, FACC, FSCAI

Franz Messerli MD

Hypertension
Comparative First-Line Effectiveness and Safety of ACE (Angiotensin-Converting Enzyme) Inhibitors and Angiotensin Receptor Blockers: A Multinational Cohort Study
Hypertension 2021 Jul 26;[EPub Ahead of Print], R Chen, MA Suchard, HM Krumholz, MJ Schuemie, S Shea, J Duke, N Pratt, CG Reich, D Madigan, SC You, PB Ryan, G Hripcsak

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading

Most Read This Week

Recently Updated